Latest / The William Blair Thinking Podcast
Biotech Breakthroughs: Gene Editing Moves Beyond the Hype
In this episode of Biotech Breakthroughs, Matt Phipps, group head of biotech research, speaks with William Blair biotech analyst Myles Minter about how gene editing is moving from early hype toward clinically validated therapies. They discuss lessons from the first approved ex vivo product and highlight key 2026 catalysts across CRISPR, base editing, RNA editing, and DNA writing.
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.